Literature DB >> 16143421

The RANKL/OPG system and bone mineral density in patients with chronic liver disease.

Alexander R Moschen1, Arthur Kaser, Sylvia Stadlmann, Gunda Millonig, Susanne Kaser, Petra Mühllechner, Andrzej Habior, Ivo Graziadei, Wolfgang Vogel, Herbert Tilg.   

Abstract

BACKGROUND/AIMS: Osteopenia and osteoporosis are common complications of chronic liver disease (CLD). Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate osteoclastogenesis and bone remodelling, and are involved in several inflammatory diseases. This study investigated the activation state of the RANKL/OPG system and its association with bone loss in CLD.
METHODS: Serum levels of OPG and sRANKL were determined in 193 patients with CLD and 56 age- and gender-matched healthy controls. Cellular sources of OPG and RANKL were determined immunohistochemically. Dual-energy x-ray absorptiometry was performed to determine bone mineral density (BMD) of lumbar spine and femoral neck.
RESULTS: sRANKL serum levels were significantly elevated in non-cirrhotic, but not cirrhotic patients compared to healthy controls. OPG serum levels were elevated 1.6-fold in non-cirrhotic and 2.8-fold in cirrhotic CLD patients. RANKL+ cells were mainly confined to portal fields, while OPG was broadly expressed. In the cirrhotic subgroup (87 patients) we observed a significantly higher OPG/sRANKL ratio in patients with osteopenia or osteoporosis of the lumbar spine and femoral neck region (T-score < -1) compared to those with normal BMD (T-score > or = -1).
CONCLUSIONS: CLD is associated with alterations in RANKL/OPG serum levels, which could modulate bone loss in CLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143421     DOI: 10.1016/j.jhep.2005.05.034

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  34 in total

1.  Osteoporosis and gastrointestinal disease.

Authors:  Seymour Katz; Stuart Weinerman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

Review 2.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

Review 3.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

4.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 5.  Osteodystrophy in chronic liver diseases.

Authors:  Pasquale Mansueto; Antonio Carroccio; Aurelio Seidita; Gaetana Di Fede; Antonio Craxì
Journal:  Intern Emerg Med       Date:  2012-01-13       Impact factor: 3.397

6.  Association between primary biliary cholangitis and osteoporosis: meta-analysis.

Authors:  Junyu Fan; Qian Wang; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2017-09-26       Impact factor: 2.980

Review 7.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

8.  Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.

Authors:  Sittisak Honsawek; Tawatchai Chaiwatanarat; Paisarn Vejchapipat; Voranush Chongsrisawat; Nutchanart Thawornsuk; Yong Poovorawan
Journal:  Pediatr Surg Int       Date:  2009-01-29       Impact factor: 1.827

Review 9.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

10.  The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.

Authors:  Inaam A Nakchbandi; Robert Lang; Barbara Kinder; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.